Carolyn Schutt Ibsen, assistant professor of biomedical engineering, OHSU School of Medicine, with a joint appointment with CEDAR,, was recognized as a Young Innovator in Cellular and Molecular Bioengineering at the 2024 Biomedical Engineering Society meeting held in October. The Young Innovator Award is issued by the journal Cellular and Molecular Bioengineering (CMBE), which selects a group of early-career faculty for their innovative and impactful bioengineering research. Dr. Schutt Ibsen’s research details the development of a new coaxial 3D bioprinting technique for remote-controlled gene delivery and was conducted with lead author Mary (Kylene) Lowrey, a biomedical engineering Ph.D. student in Dr. Schutt Ibsen’s group. Their paper is featured in the October Young Innovators Issue of CMBE. 

Luiz Bertassoni was recently selected as an inspiring Latinx/Hispanic scientist by the Fred Hutchison Cancer Center. Bertassoni was named to the Atlas of Inspiring Hispanic/Latinx Scientists, a grassroots effort to develop a showcase for the expertise, talents, and diversity of Hispanic and Latinx scientific faculty. Scientists were identified through a nomination system. “For rising generations of scientists, this atlas is about providing a forum of role models,” said Termini, an assistant professor in the Translational Sciences and Therapeutics and Human Biology Divisions at Fred Hutch. “It has the potential to reinforce the identity of Hispanic and Latinx scientists and show that it is possible to achieve careers in all these different fields.” Bertassoni is a Professor at OHSU, a member of CEDAR, and director of the Knight Cancer Precision Biofabrication Hub.

CEDAR graduate student Nikita Sehgal was awarded her oral presentation at the 2024 Northwest Society for Biomaterials Regional Symposium. Sehgal's presentation, "Dendrimer-microbubble complexes as ultrasound-activated nanocarriers for precision cancer gene therapy" received third place. Sehgal's CEDAR faculty adviser is Carolyn Schutt Ibsen; her current research focuses on developing ultrasound-responsive microbubble-nanoparticle conjugates for precision cancer therapy.

Knight Cancer Institute CEO Brian Druker recently appeared on KGW's "The Story" in a two-part interview, discussing his development of the crucial cancer-fighting medication Gleevec, the Knight's interest in furthering precision oncology, and the institute's work in advancing early detection, including the establishment of CEDAR. "We've deliberately designed it to be multidisciplinary," Druker told KGW's Pat Dooris. "So it's cancer biologists, it's mathematicians, it's engineers, it's computationalists, it's all sorts of different disciplines to try to attack a huge problem to advance the field. And I've always talked about this kind of like a Bell Labs. It's bringing lots of different disciplines together, bringing them and focusing them on a problem and then watching incredible things happen." Read or watch part one here, and part two here.

CEDAR Ph.D. students Nikita Sehgal and Kira Lynch were awarded N.L. Tartar Trust Fellowships based on their research proposals.  The fellowships award $2000 to support research endeavors and research career development in the OHSU School of Medicine, including conference attendance, equipment, and specialized lab services. Lynch's proposal investigates the role of endothelial cells in the link between cardiovascular disease and breast cancer progression. Sehgal's proposal is developing novel dendrimer-microbubble complexes as ultrasound-activated nanocarriers for precision cancer gene therapy. Sehgal was also recently awarded a professional development scholarship from Women in Science Portland.

CEDAR graduate student Kira Lynch recently received an honorable mention for the National Science Foundation's Graduate Research Fellowship Program. Every year, the National Science Foundation awards fellowships to high-potential individuals early in their careers; since the program's founding, more than 40 former fellows have been awarded the Nobel Prize, and more than 400 have been elected as members to the National Academies of Sciences, Engineering, and Medicine. Lynch studies with professor Monica Hinds and assistant professor Carolyn Schutt Ibsen, utilizing biofabrication techniques to model the tumor vasculature and study how endothelial cell state influences cancer progression in the context of 3D tissues. Every cycle the National Science Foundation receives more than 12,000 applications; Lynch is one of the 1788 students to receive an honorable mention.

CEDAR's Jose Luis Montoya Mira, a research engineer, is central to a recent story in Oregon Business profiling the Corvallis Microfluidics Tech Hub, an industry coalition led by Oregon State University. The group was recently designated as a national Tech Hub by the United State Department of Commerce's Economic Development Administration, and includes 40 institutes, companies, and municipalities, including OHSU. The hub is dedicated to bolstering the Pacific Northwest's microfluidics industry through collaboration, with a focus on bringing the technology to commercial scale. Montoya Mira utilizes microfluidics for cellular study, including research into "hybrid" cancer cells—cells that are a blend of tumor and blood cells, used by tumors to spread throughout the body.

Nima Nabavizadeh, M.D., was named chief medical officer for CEDAR. Nabavizadeh is an associate professor in the Department of Radiation Medicine and program director for the radiation oncology residency. He previously served as director of early detection clinical research at CEDAR, and he is principal investigator for a number of early detection studies, including Pathfinder 2. In his new role, Nabavizadeh will continue to lead clinical trials at CEDAR, but will also be part of the center’s leadership team, working with Sadik Esener, Ph.D., Shelley Barton, Ph.D., Beverly Emerson, Ph.D., and others in guiding CEDAR’s mission, vision and values. “It’s been so fun being a part of our early detection clinical trials group and seeing the exciting future of cancer screening first-hand. I’m also really excited for this expanded role within CEDAR,” Nabavizadeh said. “As a radiation oncologist, I have many clinical partners and colleagues across disease sites and specialties. I hope to serve as the clinical link between our clinicians and CEDAR scientists. Fostering these collaborations will maximize the impact of OHSU’s early detection scientific discoveries on patient care and public health while advancing the career of CEDAR scientists and Knight clinical faculty."

CEDAR Assistant Professor Josh Moreau received a Kuni Foundation Imagination Cancer Research Grant. The Kuni Foundation annually awards grants for up to three years to support early and mature cancer research with goals of improved detection, treatment, and outcomes. Moreau received $85,000 for investigating the role of PM2.5 air pollution in skin cancer immunity.

CEDAR Scientist Jessica Riesterer was elected as a Director to the Microanalysis Society of America (MAS). The society is a non-profit professional association dedicated to the advancement of microanalytical principles, instrumentation, and applications. MAS provides local, regional, national, and international forums for the exchange of questions and solutions regarding microanalysis problems across scientific disciplines. The more than 600 members of MAS include academic, industrial and government researchers, and commercial product developers with specialties in materials science, geology, physics, chemistry, and biological sciences. Her three-year term started in January 2024.

The National Science Foundation selected CEDAR Assistant Professor Carolyn Schutt Ibsen, Ph.D., for its Faculty Early Career Development (CAREER) Program, which supports early-career faculty who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization. Ibsen’s $615,500 award will fund her development of a 3D printable “bioink” that allows deep-penetrating ultrasound to trigger the delivery of genetic material to cells. The ultrasound waves can be focused to small spots within the 3D bioprinted structure to create desired patterns of gene delivery by activating embedded ultrasound-responsive particles.

GRAIL, a healthcare company pursuing new technologies to advance cancer early detection, recently recognized CEDAR/OHSU among the top 3 sites for enrolling diverse populations in their Pathfinder 2 multi-cancer early detection blood test study. CEDAR's clinical research team and the Knight Cancer Institute's Community Outreach and Engagement team have invested significant effort to recruit a diverse array of participants in the study, which seeks to evaluate the safety and performance of GRAIL’s MCED test in a population of individuals aged 50 years and older who are not actively being evaluated or treated for cancer. CEDAR's clinical research team has led outreach efforts in five Oregon counties, including to rural populations beyond Portland, and has made study materials available in multiple languages. Of the study's 29 sites in the US and Canada, OHSU is currently the top enroller overall. More information about the study, including how to participate, is available here.

CEDAR Directors Sadik Esener has been named interim director of the new Center for Biomedical Data Science, a collaboration with the University of Oregon. The center will empower researchers at both institutions to attack cancer with big data, combining efforts at the Knight Cancer Institute with those at the University of Oregon's Phil and Penny Knight Campus for Accelerating Scientific Insight. Esener will work closely with Bill Cresko, interim director of the UO program, as well as with scientific codirectors Xubo Song and Emek Demir, both CEDAR members. Esener says one of the early goals the newly formed leadership team will prioritize is establishing a culture that promotes innovation by initiating collaborative projects between data generators and data analysts. “A key goal of mine will be to integrate the Center within the Knight Cancer Institute,” he says. “We want to encourage strong collaboration and interaction with teams across the institute, including CEDAR, Precision Oncology, Beat AML and any interested physicians and faculty members. I believe increased communication and collaboration among these groups will have a positive impact on the Knight Cancer Institute and OHSU overall.”

GRAIL's multi-cancer early detection (MCED) test demonstrated that the test identified many cancer types that currently lack recommended screening tests, enabling target cancer diagnostic evaluations, and supporting diagnostic resolution for the majority of participants in under three months, according to a new article published in The Lancet. The test was the central component of the Pathfinder study, conducted in 6,662 adults over the age of 50 without symptoms suggestive of cancer. The study was conducted with several partner institutions; Tom Beer, former Chief Medical Officer of CEDAR, led the study at OHSU and coauthored The Lancet publication.

Research from Luiz Bertassoni, Assistant Professor with the OHSU School of Dentistry and CEDAR member, and colleagues was featured on the cover of Advanced Healthcare Materials in September 2023. The team from the Knight Cancer Precision Biofabrication Hub devised a minimally invasive strategy for repairing lost or injured tissue using bioprinted microgels laden with stem cells and endothelial cells that grow functioning blood vessels. When injected into tissue defects, newly formed capillaries in the constructs readily merge with host blood vessels and promote connective tissue formation.

CEDAR's Joshua Moreau, Assistant Professor with the OHSU Division of Oncological Sciences, is the recipient of two prestigious funding awards. Moreau, who joined CEDAR in June 2022, explores the earliest interactions between cancer and the immune system, within the tissues where cancer cells arise. He was recently awarded grants by both the Elsa U Pardee Foundation, which funds research to investigators identifying new treatments or cures for cancer, to investigate the role of skin-resident B cells in cancer; and the LEO Foundation, for his work investigating the potential role of B cells in the inflammatory skin disease hidradenitis suppurativa.

The new Knight Cancer Precision Biofabrication Hub recently secured more than $1 million to expand its capabilities, writes OHSU science reporter Joe Rojas-Burke. The hub allows Knight Cancer Institute and CEDAR researchers to engineer lab-grown organoids and other biofabricated models of human tissue, enabling exploration of fundamental disease processes like cancer within human cells in real time. “Now we have these additional funds to equip the hub with state-of-the art technologies,” said its director, and CEDAR Member, Luiz Bertassoni, D.D.S., Ph.D. “The real focus is to recreate cancer tissues using these fabrication techniques. This will let us dissect the complexities of cancers and understand the contribution of each one of these cells and tumor building blocks. It’s almost as if you had a big puzzle — and cancer is absolutely a big puzzle — and you can now separate each one of those pieces and see what each one of those pieces are doing." This approach is particularly crucial to CEDAR's mission, as there are limitations to the use of animal models to understand how human cancers grow and become life-threatening. The hub was funded by the M.J. Murdock Charitable Trust, the Knight Cancer Institute, the OHSU School of Medicine, and Bertassoni, who is an associate professor in the OHSU School of Medicine, Division of Oncological Sciences. You can read more about the Biofabrication Hub in Rojas-Burke's story.

KATU News Portland recently profiled CEDAR's efforts in recruiting participants for the Pathfinder 2 multi-cancer early detection blood test. To expand the study's reach, CEDAR has teamed up with Salem Health to recruit participants in the Salem area, building on the team's recruitment efforts in Coos, Curry and Douglas counties. The blood test searches for genomic clues of an actual cancer, including cancers that currently lack early detection tools—including pancreatic and ovarian cancers. “People around Oregon, and in the greater Salem area, will be among the first to have the opportunity to be tested,” says Nima Nabavizadeh, M.D., principal investigator on the Pathfinder 2 study. “Being at the forefront of generating new knowledge means we have the ability to bring it to our communities faster.” More information about the study, including how to participate, is available here.

CEDAR Member and Assistant Professor of Radiation Medicine Aaron Grossberg is one of three OHSU scientists to receive the 2023 Faculty Excellence and Innovation Awards, made possible by the Silver Family Innovation Fund. As part of the award, Grossberg will receive $750,000 over three years to expand his laboratory's ability to study how cancer affects the metabolism of fat and muscle, and identify new drug targets to prevent or reverse the process of cancer-related weight loss, also known as cachexia. This metabolic condition prevents the body's normal ability to gain weight and preserve strength, adversely impacting patients' fitness to receive the best treatments for their cancer.

OHSU Innovates has honored CEDAR Postdoctoral Scholar Matthew Rames as one of three Early Career Innovators for 2023. The award is given annually to a student, postdoctoral researcher or resident that shows a passion for innovation and works on novel technologies that tackle real-world problems. The honor recognizes Rames' work with the OHSU Technology Transfer Office on a project aimed at developing new ways of conjugating labels to antibodies for multiplex imaging. His work will be celebrated at the 2023 OHSU Innovation Awards on March 22, 2023. Rames earned his Ph.D. at OHSU in 2022.

The Salem Statesman Journal recently recognized OHSU's efforts at bringing clinical research to local communities, including recruiting more diverse participant populations. CEDAR's participation in the Pathfinder 2 study, which is investigating a multi-cancer early detection test via a simple blood draw, was among the effort detailed, CEDAR's Pathfinder 2 recruitment has reached beyond Portland, utilizing subsites in Coos, Curry and Douglas counties, where over 200 participants were enrolled in the study. Twenty percent were of enrollees were of diverse racial and ethnic backgrounds, and 100 percent of them were rural. All Pathfinder 2 materials are also available in Spanish. “We have multiple anecdotes of patients whose lives have certainly been changed in positive ways with the Pathfinder study,” said Nima Nabavizadeh, a radiation oncologist and principal investigator of the Pathfinder study. More information about the study, including how to participate, is available here.

The Biomedical Engineering Society's Cell and Molecular Bioengineering Conference selected CEDAR's Carolyn Schutt Ibsen, Ph.D., for its 2023 Rising Star Junior Faculty Award for her outstanding work in the field of cell and molecular bioengineering. She will be recognized at a gala dinner and provide a podium presentation in a special session at the annual conference in January. This special interest group brings together researchers with diverse scientific and clinical interests with a common goal of understanding and engineering molecules, cells, their interactions, and microenvironments in the pursuit of controlling biological processes and improving the practice of medicine.

Five CEDAR interns from OHSU's Summer Equity Research Program (Shawn Ichikawa, Chivon Ou, Shelby Sawyer, Matthew Tokuda and Gavin Magill) competed in the International Genetically Engineered Machines (iGem) Competition in Paris from October 26 to October 28. The team developed its cancer early detection project over the summer with CEDAR mentors Michael Brasino, Joshua Saldivar, and Carlos Origel Alberto Marmolejo. The project seeks to create a more accessible, cost-effective alternative to the present models of detecting the overexpression of c-Myc mRNA. Their aim was to create a cancer early detection diagnostic tool that most clinicians can acquire in order to determine if their patients may have cancer by taking their patient’s blood sample and inputting that sample onto an agar plate with bioengineered E. coli bacteria, which is designed to proliferate only in the presence of cancerous c-Myc mRNA. You can read more about their project at iGem's Wiki.

The Pathfinder 2 study—designed to evaluate the performance of a multi-cancer early detection test that can detect 50 types of cancer through a simple blood draw—has recently expanded across Oregon. OHSU and CEDAR have collaborated with several Oregon health systems to make the study, and test, available to residents across the state. This greatly increases the study's accessibility, particularly for Hispanic/Latino, Asian/Pacific Islander, and Native American/Alaska Native communities. It now covers residents in Coos Bay, Salem Bend, Hood River, and the Dalles, as well as surrounding areas. “Having the opportunity to bring this cutting-edge technology to more people across Oregon is so rewarding,” says Tiffani Howard, Ph.D., scientific liaison to GRAIL and research assistant director for community outreach and engagement, OHSU Knight Cancer Institute. “The Knight Cancer Institute is dedicated to serving people across our entire state. We know it’s not feasible for everyone who is interested in participating in this cancer early detection study to travel to Portland; now they have options closer to home.” The study is open to those who are aged 50 or older, have never been diagnosed with cancer or have been cancer-free for at least three years. Contact them at pathfinder@ohsu.edu or 503-418-8150, or visit the study webpage.

CEDAR researchers have devised an accurate and novel way to test blood to see if a pre-cancerous condition is escalating to outright cancer—potentially enabling treatment early in tumor development when cancer is more likely to be curable. The team, led by Thuy Ngo, a member of CEDAR and associate professor of molecular and medical genetics in the OHSU School of Medicine, developed a test that looks for cell-free messenger RNA biomarkers to distinguish multiple myeloma blood samples from non-cancer samples with 90% accuracy, and multiple myeloma from its pre-malignant condition with 100% accuracy. They were able to distinguish liver cancer samples from non-cancer with 93 to 100% accuracy, and liver cancer from cirrhosis with 100% accuracy. The research, published in NPJ Precision Oncology, lays the foundation for developing inexpensive assays that measure levels of cell-free RNA in blood for a small panel of genes that can differentiate cancer from pre-malignant conditions; Ngo and OHSU have filed a patent on their findings. More information on this research is available from OHSU News.

Cancer early detection research can transform patient survival, but there are still significant obstacles preventing the translation of new research findings into the clinical setting, assert leaders of the field, including CEDAR's Sadik Esener and the Knight Cancer Institute's Lisa Coussens, in a new publication in the journal Science. Around half of all cancers are diagnosed at an advanced stage, despite the fact that treatments stand the best chance at improving survival when implemented early. “Late-stage detection of cancer is a global problem that is exacerbated in resource poor settings, demonstrating that equity is a considerable challenge,” the authors observe. “Patients diagnosed with later-stage cancer can miss the window for curative intervention, and expensive later-stage systemic treatments are often associated with severe side effects and worse outcomes.” At CEDAR, researchers are investigating cancer's early changes, and applying this knowledge to work on new, inexpensive screening tests, determining which cancers need vigorous early intervention, and directing precision therapies to reduce drug toxicity. You can read more about the article's findings on the Knight Cancer Institute's Cancer Translated blog.

CEDAR Postdoctoral Scholar Sebnem (Ece) Eksi recently spoke with the Knight Cancer Institute's Cancer Translated blog, discussing findings that could help identify more dangerous prostate cancers earlier, giving researchers new tools to stop them. Only a fraction of prostate cancers become life-threatening, but predicting which ones is challenging. Eksi and her team found that two signaling proteins used by nerve cells can become active in and around prostate tumors, and may play a role in driving the cancers to be deadly. She discussed the discovery, published in Nature Communications, with Cancer Translated, including how the findings could help molecular biologists working on other cancer types.

CEDAR Member Kemal Sonmez was recognized as a Distinguished Alumnus for 2021 by the University of Maryland College Park, "for their leadership and meritorious contributions to the field of engineering, their humanitarian efforts, and the application of their engineering education to other disciplines." Sonmez received his Ph.D. at the University of Maryland College Park.

CEDAR graduate student Kylene Lowrey took home first place in the poster session at the All Oregon Bioengineering Symposium. She presented "3D Bioprinting Ultrasound-Responsive Materials for Cellular Manipulation in 3D Tissue Constructs," which also included CEDAR authors Luiz Bertassoni and Carolynn Schutt. At CEDAR, Lowrey works on creating cell cultures in hydrogels and using ultrasound to facilitate localized release of microbubbles in these hydrogels. She worked for several years in materials science, specifically creating unique inorganic nanoarchitectures.

CEDAR researchers Jose Luis Montoya Mira and Ajay Sapre, alongside teammates Kyle Gustafson, Gene Tu, Jared Fischer, Roger Chiu and Sadik Esener published "Label-free enrichment of rare unconventional circulating neoplastic cells using a microfluidic dielectrophoretic sorting device" in Communications Biology on September 24. The team reported on the development of a label-free dielectrophoretic microfluidic platform facilitating enrichment of CHCs in a high-throughput and rapid fashion by depleting healthy peripheral blood mononuclear cells (PBMCs). This represents a promising approach to non-invasively analyzing tumor cells from patients.

Thuy Ngo, Ph.D., has received a Peer Reviewed Cancer Research Program Idea Award from the Department of Defense for a project to identify blood biomarkers for early diagnosis and treatment monitoring of liver cirrhosis and cancer. Ngo is an Assistant Professor of Molecular and Medical Genetics in the OHSU School of Medicine and a member of CEDAR, the Knight Cancer Institute's Cancer Early Detection Advanced Research Center. Liver cancer, or hepatocellular carcinoma, is the fourth leading cause of cancer-related deaths worldwide. Current clinical blood tests have low sensitivity to detect liver cancer at early stages and are not effective for the reliable diagnosis of cirrhosis, which puts people at high risk of liver cancer. Patients with liver cancer are often diagnosed with inoperable disease. The Department of Defense award — $769,996 total — is supporting Ngo's proposal to identify cell-free RNA biomarkers (including messenger RNA, circular RNA, transposable elements and microbial transcripts) that can detect cirrhosis and monitor its progression to liver cancer. 

OHSU physician-scientist Aaron Grossberg, M.D., Ph.D. was among the first recipients of the new Science of the Patient Award from the American Association for Cancer Research (AACR) and The Mark Foundation for Cancer Research. Grossberg is a co-investigator alongside principle investigator Daniel L. Marks, M.D., Ph.D. on research investigating the wasting syndrome cachexia in pancreatic cancer. In advanced cancer and other diseases, cachexia can erode quality of life and hasten death. Marks and Grossberg are focusing on the role of the autonomic and neuroendocrine stress responses in pancreatic cancer cachexia. Marks is a Professor of Pediatrics and Senior Associate Dean for Research in the OHSU School of Medicine. Grossberg is an Assistant Professor of Radiation Medicine with a joint appointment with CEDAR and the Brenden-Colson Center for Pancreatic Care. The Science of the Patient Award was established to stimulate groundbreaking research exploring the influence of biology of the patient on cancer genesis, development, treatment, and survivorship.

Carolyn Schutt Ibsen, Ph.D. is an Assistant Professor of Biomedical Engineering in the OHSU School of Medicine and a member of CEDAR. In a recent interview with the Knight Cancer Institute's Cancer Translated blog, she discusses her research, which investigates the use of "energy-responsive" biomaterials that can be controlled remotely using ultrasound to model cancer progression, as well as to guide the repair of living tissue. In the wide-ranging conversation with CEDAR Postdoctoral Scholar Kathryn Baker, Ph.D., Schutt Ibsen discusses her work's potential the challenges of modeling cancer progression, and how CEDAR's multi-disciplinary environment is critical for her research.

The Knight Cancer Institute at Oregon Health & Science University is one of five sites across the country selected by GRAIL, Inc., a health care company dedicated to detecting cancer early, to join a study designed to improve early detection of cancer. The PATHFINDER study will evaluate the implementation of an investigational early detection test that has been designed to test many types of cancer through a single blood draw, into clinical practice for the first time.

The OHSU Knight Cancer Institute, together with collaborators across the U.S. and the U.K., announced the formation of the International Alliance for Cancer Early Detection, or ACED. This new alliance is formed by the coordinated efforts of Cancer Research UK, Canary Center at Stanford University, the University of Cambridge, the OHSU Knight Cancer Institute, University College London (UCL) and the University of Manchester.

Women in the Knight Cancer Institute are making significant advancements in their fields. Onward, the magazine of the OHSU Foundation, profiled nine of them. Tackling a problem as big as cancer is often a matter of moving one step forward, two steps back. It requires patience and persistence and an unwavering belief that the answer is out there — at least, that’s the way Beverly Emerson, Ph.D., sees it.

Few people know the wide variety of careers available to those who may be interested in working in the field of cancer. Knight Cancer Institute scientists share their experiences, discuss their work, and talk about the ways they mentor and develop young people so they can be a part of the effort to end cancer as we know it. Knight School is a series of community-facing science talks designed to educate, entertain, and inspire with stories told by Knight Cancer researchers, clinicians and patients.

Learn about the history of cancer treatment, what's possible today and what's next in treatment and therapy as we work to end cancer as we know it. Watch the Knight School session.

Hisham Mohammed, Ph.D., is an associate scientist at the OHSU Knight Cancer Institute Cancer Early Detection Advanced Research (CEDAR) center, one of the largest initiatives in the world focused on research to enable the detection of cancers at an earlier, more treatable stage. At the University of Cambridge, UK, while working as a Ph.D. student, Mohammed invented a method to analyze and understand protein complexes more efficiently — a method now being used in labs across the world. Importantly, this method allowed him to discover a pivotal role for the hormone progesterone in regulating breast cancer.

Leaders at the Knight Cancer Institute know that scientific discoveries are not guaranteed, even with $1 billion to spend looking for answers. They also know that some of the world’s most dramatic discoveries happened by accident, when scientists were looking for something completely different than what they ended up finding. Collaborative, multi-disciplinary work — a kind of intellectual cross-pollination that can lead to surprising results — is the goal at OHSU.

Sadik Esener, Ph.D., is building a multidisciplinary team to reveal the evolutionary biology of cancer to develop low-cost screening, determine which cancers to aggressively treat and leverage precision therapies to minimize toxicity. The Wendt Family Chair professor of biomedical engineering in the OHSU School of Medicine and director of the Knight Cancer Institute Cancer Early Detection Advanced Research center (CEDAR), Dr. Esener and his team's goal is to find and eliminate lethal cancers at the earliest stage with little harm to the patient.